Disparities in Tumor Mutational Burden, Immunotherapy Use, and Outcomes Based on Genomic Ancestry in Non–Small-Cell Lung Cancer | Zendy

Otis W. Brawley | Zendy; Patricia Luhn | Zendy; Deonna Reese-White | Zendy; Uzor C. Ogbu | Zendy; Sriraman Madhavan | Zendy; Gerren Wilson | Zendy; Meghan Cox | Zendy; Altovise Ewing | Zendy; Christian Hammer | Zendy; Nicole Richie | Zendy

Open Access

Disparities in Tumor Mutational Burden, Immunotherapy Use, and Outcomes Based on Genomic Ancestry in Non–Small-Cell Lung Cancer

Author(s) -

Otis W. Brawley,

Patricia Luhn,

Deonna Reese-White,

Uzor C. Ogbu,

Sriraman Madhavan,

Gerren Wilson,

Meghan Cox,

Altovise Ewing,

Christian Hammer,

Nicole Richie

Publication year - 2021

Publication title -

jco global oncology

Language(s) - English

Resource type - Journals

ISSN - 2687-8941

DOI - 10.1200/go.21.00309

Subject(s) - medicine , hazard ratio , lung cancer , interquartile range , oncology , genetic genealogy , cancer , population , confidence interval , environmental health

In patients with advanced non-small-cell lung cancer (aNSCLC), tumor mutational burden (TMB) may vary by genomic ancestry; however, its impact on treatment outcomes is unclear. This retrospective, observational study describes treatment patterns of patients with aNSCLC by genomic ancestry and electronic health record (EHR)-reported race and/or ethnicity and evaluates differences in TMB, cancer immunotherapy (CIT) access, and treatment outcomes across racial and ancestral groups.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research